Biogen Idec sale could have big impact in Boston

With Biogen Idec on the market, reporters are delving into the possibilities for the company and the potential fallout in the Boston biotech cluster that the company calls home. In one scenario, Cambridge, MA-based Biogen Idec and its big research operations are gobbled up whole by a Big Pharma company, with the region losing one of its oldest and biggest marquee names. But the biotech boosters in Beantown prefer to look on the sunny side of things, speculating about a deal that could enhance local work on biologics. Right now, biotech companies in general are fetching a premium as pharma buys in to the next generation of therapies.

Biogen Idec's quarterly profit, meanwhile, slid 24 percent on a charge related to the consolidation of Cardiokine.

- read the report from The Boston Globe
-
here's a report from the Wall Street Journal on Biogen Idec's numbers

Related Articles:
Biogen Idec in play after Icahn makes his move. Report
Boston biotech booming as scientific research flourishes. Report
The growing power of biotech. Report
Biotech stocks surge as investors anticipate buyouts. Report
Speculation soars over Pfizer's interest in biotech. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me